FDA Advisory Committee Recommends Approval of Sanofi and Regeneron's Praluent(r) (alirocumab) Injection for Patients with Hypercholesterolemia
June 09, 2015 18:47 ET
|
SANOFI
PARIS and TARRYTOWN, N.Y., June 9, 2015 (GLOBE NEWSWIRE) -- Sanofi and Regeneron Pharmaceuticals, Inc. today announced that the Endocrinologic and Metabolic Drugs Advisory Committee (EMDAC) of the...
Sanofi Announces Top-Line Results for Cardiovascular Outcomes Study of Lyxumia(r) (lixisenatide)
March 19, 2015 02:11 ET
|
SANOFI
PARIS, March 19, 2015 (GLOBE NEWSWIRE) -- Sanofi announced today top-line results of the Phase IIIb ELIXA cardiovascular outcomes study, which compared lixisenatide to placebo in a high-risk...
Sanofi, Regeneron: 18-Month Results of ODYSSEY LONG TERM Trial with Praluent(TM) (alirocumab) Published in The New England Journal of Medicine
March 15, 2015 11:14 ET
|
SANOFI
Sanofi and Regeneron Announce 18-Month Results of ODYSSEY LONG TERM Trial with Praluent (TM) (alirocumab) Published in The New England Journal of Medicine
- Robust and consistent LDL-C lowering...
Sanofi and MannKind Announce Global Licensing Agreement for Afrezza(R) (insulin human) Rapid-Acting Inhaled Insulin
August 11, 2014 01:12 ET
|
SANOFI
PARIS and VALENCIA, Calif., Aug. 11, 2014 (GLOBE NEWSWIRE) -- Sanofi (EURONEXT: SAN and NYSE: SNY) and MannKind Corporation (Nasdaq: MNKD) announced today that they have entered into a worldwide...
First Ever Dengue Vaccine Candidate To Show Efficacy Against Dengue Fever and Dengue Haemorrhagic Fever in Asia
July 10, 2014 19:07 ET
|
SANOFI
- 88.5% reduction of Dengue Haemorrhagic Fever shown in detailed analyses of world's first phase III efficacy study published in The Lancet -
- Two thirds reduction in hospitalization observed...
Sanofi and Regeneron Announce Positive Results from Phase 2b Study of Dupilumab in Patients with Moderate-to-Severe Atopic Dermatitis
July 09, 2014 17:09 ET
|
SANOFI
PARIS and TARRYTOWN, N.Y., July 9, 2014 (GLOBE NEWSWIRE) -- Sanofi (EURONEXT : SAN and NYSE : SNY) and Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced positive results from a Phase 2b...
Sanofi Reports Positive Phase 3 Results for Toujeo(R)
June 14, 2014 13:09 ET
|
SANOFI
Sanofi Reports Positive Phase 3 Results for Toujeo®
(insulin glargine [rDNA origin] injection, 300 U/mL)
- Meta-analysis of three late-stage trials in people with type 2 diabetes shows...
Sanofi and Lilly announce licensing agreement for Cialis(R) (tadalafil) OTC
May 28, 2014 00:08 ET
|
SANOFI
Sanofi and Lilly announce licensing agreement for Cialis® (tadalafil) OTC
- Companies anticipate providing over-the-counter (OTC) product to treat erectile dysfunction after...
Shantha's Pentavalent Pediatric Vaccine prequalified by World Health Organization
May 05, 2014 01:06 ET
|
SANOFI
- Shan5(TM) is the first vaccine jointly developed by the Indian company
and its parent company Sanofi Pasteur -
- WHO's decision allows for the purchase of Shan5(TM) by United Nations agencies...
Sanofi Files Suit in The U.S. To Defend Its Patent Rights on Lantus(R) and Lantus(R) SoloStar(R)
January 30, 2014 17:12 ET
|
SANOFI
PARIS, Jan. 30, 2014 (GLOBE NEWSWIRE) -- Sanofi (EURONEXT:SAN) (NYSE:SNY) announced today that it filed a patent infringement suit against Eli Lilly and Company ( "Lilly") on January 30, 2014 in the...